Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1872
http://purl.obolibrary.org/obo/NCIT_C1872
|
|---|---|
| Preferred Name | Midostaurin |
| Definitions |
A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors. |
|---|---|
| prefLabel | Midostaurin
|
| label | Midostaurin
|
| CHEBI_ID | CHEBI:63452
|
| PDQ_Closed_Trial_Search_ID | 462346
|
| code | C1872
|
| Has_Target | |
| prefixIRI | NCIT:C1872
|
| in_subset |
See more
See less
|
| Display_Name | Midostaurin
|
| Preferred_Name | Midostaurin
|
| FDA_UNII_Code | ID912S5VON
|
| Is_PCDC_AML_Permissible_Value_For_Variable | |
| Contributing_Source |
CTRP
FDA
PCDC
|
| Chemical_Formula | C35H30N4O4
|
| Maps_To | Midostaurin
|
| CAS_Registry | 120685-11-2
|
| NCI_Drug_Dictionary_ID | 462346
|
| Legacy Concept Name | Midostaurin
|
| type | |
| ALT_DEFINITION | A substance that is being studied in the treatment of leukemia. It belongs to the family of drugs called protein kinase inhibitors.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 462346
|
| Accepted_Therapeutic_Use_For | acute myeloid leukemia (AML) who are FLT3 mutation-positive (FLT3+)
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0526371
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |